2025年6月23日,香港知名投行丽奥资产发布健康之路(2587.HK)深度研究报告,首次覆盖给予买入评级,目标价68.5港元,相较于现价存在218%的上涨空间。国内领先的全周期数字健康医疗服务平台,在企业服务及数字营销服务上的不断扩展和深化。公司作为全国数字健康医疗服务平台的领军企业,凭借其创新能力将BC端用户深度融合,创造协同效应,实现业务高速增长。公司依托数字化平台积累建设,加速与药企、...
Source Link2025年6月23日,香港知名投行丽奥资产发布健康之路(2587.HK)深度研究报告,首次覆盖给予买入评级,目标价68.5港元,相较于现价存在218%的上涨空间。国内领先的全周期数字健康医疗服务平台,在企业服务及数字营销服务上的不断扩展和深化。公司作为全国数字健康医疗服务平台的领军企业,凭借其创新能力将BC端用户深度融合,创造协同效应,实现业务高速增长。公司依托数字化平台积累建设,加速与药企、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.